Matsuda Takuya, Namisaki Tadashi, Shibamoto Akihiko, Asada Shohei, Tomooka Fumimasa, Kubo Takahiro, Koizumi Aritoshi, Tanaka Misako, Iwai Satoshi, Inoue Takashi, Tsuji Yuki, Fujinaga Yukihisa, Nishimura Norihisa, Sato Shinya, Kitagawa Koh, Kaji Kosuke, Mitoro Akira, Asada Kiyoshi, Takaya Hiroaki, Noguchi Ryuichi, Akahane Takemi, Yoshiji Hitoshi
Department of Gastroenterology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Nara, Japan.
Department of Evidence-Based Medicine, Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Nara, Japan.
Int J Mol Sci. 2025 Apr 28;26(9):4184. doi: 10.3390/ijms26094184.
Covert hepatic encephalopathy (CHE) can worsen the quality of life and prognosis of patients with cirrhosis. We analyzed the risk factors of CHE and identified patients at high risk for overt hepatic encephalopathy (HE) who would benefit from therapeutic interventions. We included 145 patients without a history of or treatment for overt HE. Patients were divided into the CHE and no-CHE groups ( = 91 and 54, respectively). CHE had a score above the age-based cutoff value of one of the neuropsychological tests, such as the Stroop and number connection tests. CHE prevalence was 62.8% ( = 91). Compared with the no-CHE group, the CHE group had significantly lower serum zinc and albumin levels. Multiple logistic regression analysis identified serum zinc levels at a cutoff value of 74 µg/dL. Subclinical zinc deficiency showed a diagnostic performance of 55.6% sensitivity and 81.5% specificity for CHE. Blood ammonia levels and liver functional reserves were not predictive of CHE. Compared with patients with zinc levels < 74 µg/dL ( = 102), those with ≥74 µg/dL ( = 43) had significantly lower CHE prevalence and better hepatic functional reserve. Subclinical zinc deficiency was associated with CHE occurrence in patients with cirrhosis without a history of or treatment for overt HE. Measurement of zinc levels facilitates early detection of CHE by neuropsychological testing.
隐性肝性脑病(CHE)会恶化肝硬化患者的生活质量和预后。我们分析了CHE的危险因素,并确定了可能从治疗干预中获益的显性肝性脑病(HE)高危患者。我们纳入了145例无显性HE病史或未接受过相关治疗的患者。患者被分为CHE组和非CHE组(分别为91例和54例)。CHE在一项基于年龄的神经心理学测试(如斯特鲁普测试和数字连接测试)中的得分高于临界值。CHE患病率为62.8%(n = 91)。与非CHE组相比,CHE组的血清锌和白蛋白水平显著降低。多因素logistic回归分析确定血清锌水平的临界值为74 µg/dL。亚临床锌缺乏对CHE的诊断性能为灵敏度55.6%,特异度81.5%。血氨水平和肝功能储备不能预测CHE。与锌水平<74 µg/dL的患者(n = 102)相比,锌水平≥74 µg/dL的患者(n = 43)CHE患病率显著更低,肝功能储备更好。在无显性HE病史或未接受过相关治疗的肝硬化患者中,亚临床锌缺乏与CHE的发生有关。检测锌水平有助于通过神经心理学测试早期发现CHE。